← Back to Search

Nonsteroidal Anti-inflammatory Drug

Aspirin for Pre-eclampsia

Phase 2
Recruiting
Led By Aleha Aziz, MD, MPH
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 weeks postpartum
Awards & highlights

Study Summary

This trialwill study the effects of low-dose aspirin on women with severe preeclampsia post-delivery, to see if it helps improve their condition.

Eligible Conditions
  • Postpartum preeclampsia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 weeks postpartum
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 weeks postpartum for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Flow-Mediated Dilation (FMD)
Secondary outcome measures
Change in Diastolic blood pressure
Body Weight Changes
Magnesium sulfate re-administration
+3 more

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: Healthy Controls GroupActive Control1 Intervention
Subjects who are healthy volunteers (n = 10) without severe preeclampsia prior to delivery.
Group II: Low-Dose Aspirin (LDA) Intervention GroupActive Control1 Intervention
Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take 81mg of aspirin daily for up to 3 weeks postpartum, starting within 4 days after delivery.
Group III: Placebo Control GroupPlacebo Group1 Intervention
Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take placebo oral capsule daily for up to 3 weeks postpartum, starting within 4 days after delivery.

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor
1,431 Previous Clinical Trials
2,460,733 Total Patients Enrolled
Aleha Aziz, MD, MPH5.05 ReviewsPrincipal Investigator - Columbia University
Columbia University
5Patient Review
Doctor Aziz is one of the best doctors I have ever had. Not only she is very knowledgeble and professional, she is also very caring and loving person. My husband and I were referred to Columbia Presbyterian Hospital due to complex pregnancy with my twin girls. Doctor Aziz made sure we feel comfortable and was very detailed oriented when explaining anything related to my health. She spoke in a way that was easy to understand. She also delivered by twin girls and we are forever thankful for that! I highly recommend her to anyone who need the best possible care from one of the most caring doctors!
Natalie Bello, MD, MPHPrincipal InvestigatorAssistant Professor of Medicine

Media Library

Aspirin (Nonsteroidal Anti-inflammatory Drug) Clinical Trial Eligibility Overview. Trial Name: NCT03667326 — Phase 2
Pre-eclampsia Research Study Groups: Healthy Controls Group, Low-Dose Aspirin (LDA) Intervention Group, Placebo Control Group
Pre-eclampsia Clinical Trial 2023: Aspirin Highlights & Side Effects. Trial Name: NCT03667326 — Phase 2
Aspirin (Nonsteroidal Anti-inflammatory Drug) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03667326 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Postpartum Low-Dose Aspirin and Preeclampsia
Aleha Aziz 2019. "Postpartum Low-Dose Aspirin and Preeclampsia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03667326.
All > Preeclampsia > Durlaza
~18 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top